Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Top Cited Papers
Open Access
- 1 June 2015
- journal article
- review article
- Published by Elsevier BV in Advanced Drug Delivery Reviews
- Vol. 87, 46-51
- https://doi.org/10.1016/j.addr.2015.01.008
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNSNucleic Acids Research, 2013
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular AtrophyScience Translational Medicine, 2011
- Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytesNucleic Acids Research, 2011
- Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose StudyClinical Cancer Research, 2010
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, 2010
- A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced CancerClinical Cancer Research, 2008
- Antisense oligonucleotide therapy for neurodegenerative diseaseJCI Insight, 2006
- Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomersCurrent Opinion in Pharmacology, 2005
- Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense DrugsJournal of Biological Chemistry, 2004